

The Efficacy and Safety of Saxenda Injection for Weight Loss

Mohammed Saad Mohammed Alqahtani

Corresponding Author, Lab Tech, Eradah Hospital and Mental Health, AlKharj, SA

Publication Date: 6th Feb 2022

Abstract

Saxenda (liraglutide) is a medication approved by the US Food and Drug Administration (FDA) for chronic weight control. Saxenda mimics the effects of a naturally occurring hormone called GLP-1, which helps regulate appetite and food intake. Clinical studies have examined the effectiveness and safety of Saxenda for weight loss in obese or overweight people. These studies have shown that Saxenda, when combined with a calorie-restricted diet and increased physical activity, can lead to significant weight loss. In a clinical trial called SCALE Obesity and Prediabetes, which included more than 3,700 participants, Saxenda was compared with placebo (an inactive substance). After 56 weeks of treatment, participants who received Saxenda lost an average of 8.4% of their body weight, while participants who received a placebo lost an average of 2.8%. In addition, people treated with Saxenda were 5% or more likely to gain clinically significant weight compared to the placebo group. It should be noted that individual results may vary and the degree of weight loss achieved with Saxenda may depend on a variety of factors, such as: B. Adherence to the recommended diet and exercise program. From a safety perspective, Saxenda was generally well tolerated in clinical trials.

Keywords: Saxenda, medication, injection, body loss

Introduction:

Saxenda (liraglutide) is a medication that is approved by the U.S. Food and Drug Administration (FDA) for chronic weight management. It is an injectable formulation of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for the treatment of type 2 diabetes. Saxenda works by mimicking the effects of a naturally occurring hormone called GLP-1, which helps regulate appetite and food intake.

Clinical studies have evaluated the efficacy and safety of Saxenda for weight loss in individuals with obesity or overweight. These studies have shown that Saxenda, when used in conjunction with a reduced-calorie diet and increased physical activity, can lead to significant weight loss.

In a clinical trial called SCALE Obesity and Prediabetes, which involved over 3,700 participants, Saxenda was compared to a placebo (inactive substance). After 56 weeks of treatment, participants who received Saxenda experienced an average weight loss of 8.4% of their initial body weight, while those who received the placebo had an average weight loss of 2.8%. Additionally, individuals treated with Saxenda were more likely to achieve clinically meaningful weight loss of 5% or more compared to the placebo group.

It's important to note that individual results may vary, and the amount of weight loss achieved with Saxenda can depend on various factors such as adherence to the recommended diet and exercise regimen.

Regarding safety, Saxenda has been generally well-tolerated in clinical trials. However, it is not without potential side effects. The most common side effects reported include nausea, diarrhea, constipation, vomiting, low blood sugar (hypoglycemia) when used with certain diabetes medications, and decreased appetite. In rare

cases, serious side effects such as pancreatitis (inflammation of the pancreas) and gallbladder problems have been reported.

Saxenda is available by prescription only, and its use should be supervised by a healthcare professional. It is important to discuss the potential risks and benefits of Saxenda with your doctor to determine if it is an appropriate option for you, taking into consideration your individual medical history and any other medications you may be taking.

Obesity has become a global epidemic, with its prevalence steadily increasing over the years. As a result, there is a pressing need for effective interventions to combat this health issue. Saxenda, a once-daily injectable medication containing liraglutide, has emerged as a potential solution for weight loss. This essay aims to explore the efficacy and safety of Saxenda injection as a treatment option for weight loss.

Efficacy of Saxenda Injection:

Saxenda works by mimicking the action of a hormone called glucagon-like peptide-1 (GLP-1) in the body. GLP-1 is produced in the gut and helps regulate appetite, food intake, and glucose metabolism. By activating GLP-1 receptors in the brain, Saxenda increases feelings of satiety, leading to reduced hunger and decreased food intake. Clinical trials evaluating the efficacy of Saxenda have shown promising results.

In a randomized, double-blind placebo-controlled trial conducted on individuals with obesity or overweight, weight loss with Saxenda was significantly greater compared to the placebo group. Over a 56-week period, participants administered Saxenda achieved an average weight loss of 8.4%, whereas the placebo group experienced a weight loss of only 2.8%. The study also highlighted the sustained effect of Saxenda, emphasizing the importance of long-term therapy for obesity management.

Furthermore, Saxenda has demonstrated superiority over other weight loss medications, such as orlistat. In a comparative study, Saxenda proved to be more effective in achieving weight loss and improving cardiometabolic risk factors. This evidence suggests that Saxenda injection can be a valuable option for individuals struggling with obesity.

Safety Profile of Saxenda Injection:

As with any medication, assessing the safety profile is crucial, particularly for long-term use. Saxenda has been extensively studied in clinical trials, and its side effects are well-documented. The most commonly reported side effects include gastrointestinal symptoms such as nausea, vomiting, diarrhea, and constipation. These adverse events are generally mild to moderate in nature and tend to subside over time.

In rare cases, Saxenda has been associated with acute pancreatitis, a potentially severe condition. However, the incidence of pancreatitis with Saxenda is low, and the overall risk-benefit ratio remains favorable. It is important for healthcare professionals to carefully monitor patients for any signs or symptoms of pancreatitis during Saxenda therapy. Additionally, Saxenda carries a warning regarding the risk of thyroid C-cell tumors based on animal studies; however, this risk appears to be negligible in humans.

Patient Selection and Monitoring:

Saxenda injection is indicated for use in adults with a body mass index (BMI) of 30 kg/m² or greater (obesity) or a BMI of 27 kg/m² or greater (overweight) with at least one weight-related comorbidity, such as hypertension, type 2 diabetes, or dyslipidemia. Prior to initiating treatment, a comprehensive assessment should be conducted to evaluate the patient's suitability, including an assessment of cardiovascular risk factors and a review of medications that may interact with Saxenda.

In terms of monitoring, regular follow-up visits are essential for patients receiving Saxenda injection. Weight, blood pressure, heart rate, and adverse effects should be routinely assessed to ensure an optimal response to

therapy and to address any potential concerns promptly. Close collaboration between patients and healthcare professionals is crucial in achieving favorable outcomes.

Conclusion:

Saxenda injection holds promise as an effective tool in weight management for individuals with obesity or overweight. Its ability to reduce hunger and promote satiety has been proven in clinical trials, and comparative studies have shown its superiority over other weight loss medications. Importantly, Saxenda has a well-documented safety profile, with gastrointestinal symptoms being the primary side effects. Patient selection, monitoring, and close collaboration between patients and healthcare professionals are essential to maximize the benefits of Saxenda therapy.

References

1. [1.](#) Jensen, M.D., Ryan, D.H., Apovian, C.M., et al. (2014) 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. *JACC*, 63, 2985-3023.
<http://dx.doi.org/10.1016/j.jacc.2013.11.004>
2. [2.](#) Ogden, C.L., Carroll, M.D., Kit, B.K. and Flegal, K.M. (2014) Prevalence of Childhood and Adult Obesity in the United States, 2011-2012. *JAMA*, 311, 806-814.
<http://dx.doi.org/10.1001/jama.2014.732>
3. [3.](#) Centers for Disease Control and Prevention. Rates of Diagnosed Diabetes per 100 Civilian, Non-Institutionalized Population, by Age, United States, 1980-2014.
<http://www.cdc.gov/diabetes/statistics/prev/national/figbyage.htm>
4. [4.](#) Guh, D.P., Zhang, W., Bansback, N., et al. (2009) The Incidence of Co-Morbidities Related to Obesity and Overweight. A Systematic Review and Meta-Analysis. *BMC Public Health*, 9, 1-20.
<http://dx.doi.org/10.1186/1471-2458-9-88>
5. [5.](#) Mokdad, A.H., Ford, E.S., Bownman, B.A., et al. (2003) Prevalence of Obesity, Diabetes, and Obesity-Related Health Risk Factors, 2001. *JAMA*, 289, 76-79.
<http://dx.doi.org/10.1001/jama.289.1.76>
6. [6.](#) Centers for Disease Control and Prevention. Potentially Preventable Deaths from the Five Leading Causes of Death-United States, 2008-2010.
<http://www.cdc.gov/mmwr/pdf/wk/mm6317.pdf>
7. [7.](#) James, W.P., Caterson, I.D., Coutinho, W., et al. (2010) Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects. *NEJM*, 363, 905-917.
<http://dx.doi.org/10.1056/NEJMoa1003114>
8. [8.](#) US Food and Drug Administration. Guidance for Industry Developing Products for Weight Management.

<http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071612.pdf>

[Citation Time(s):1]

9. [9.](#) Erick, H., Stimmler, L., Hlad, C.J., et al. (1964) Plasma Insulin Response to Oral and Intravenous Glucose Administration. The Journal of Clinical Endocrinology & Metabolism, 24, 1076-1082.
<http://dx.doi.org/10.1210/jcem-24-10-1076>
10. [10.](#) Kazafeos, K. (2011) Incretin Effect: GLP-1, GIP, DPP4. Diabetes Research and Clinical Practice, 93, S32-s36.
[http://dx.doi.org/10.1016/S0168-8227\(11\)70011-0](http://dx.doi.org/10.1016/S0168-8227(11)70011-0)
11. [11.](#) McIntyre, N., Holdsworth, C.D. and Turner, D.S. (1964) New Interpretations of Oral Glucose Tolerance. The Lancet, 2, 20-21.
[http://dx.doi.org/10.1016/S0140-6736\(64\)90011-X](http://dx.doi.org/10.1016/S0140-6736(64)90011-X)